{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:26Z","timestamp":1790361686979,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omtm.2024.101211","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T13:45:48Z","timestamp":1707918348000},"page":"101211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rationally engineered novel AAV capsids for intra-articular gene delivery"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8607-2268","authenticated-orcid":false,"given":"Wenjun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susi Liu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizette","family":"Herrschaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jude","family":"Samulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4397-4561","authenticated-orcid":false,"given":"Chengwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101211_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","article-title":"Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation \u2014 United States, 2013\u20132015","volume":"66","author":"Barbour","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.omtm.2024.101211_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780330302","article-title":"Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtm.2024.101211_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/tcrm.2006.2.2.207","article-title":"Rituximab and its potential for the treatment of rheumatoid arthritis","volume":"2","author":"Bryant","year":"2006","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.omtm.2024.101211_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13075-015-0731-1","article-title":"Abatacept decreases disease activity in a absence of CD4(+) T\u00a0cells in a collagen-induced arthritis model","volume":"17","author":"Jansen","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.omtm.2024.101211_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13075-016-1176-x","article-title":"What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?","volume":"18","author":"Humphreys","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/intimm\/dxs041","article-title":"Intra-articular gene delivery of CTLA4-FasL suppresses experimental arthritis","volume":"24","author":"Zhang","year":"2012","journal-title":"Int. Immunol."},{"key":"10.1016\/j.omtm.2024.101211_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/hum.2017.181","article-title":"Gene Delivery to Joints by Intra-Articular Injection","volume":"29","author":"Evans","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.15585\/mmwr.mm7040a2","article-title":"Prevalence of Arthritis and Arthritis-Attributable Activity Limitation - United States, 2016-2018","volume":"70","author":"Theis","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.omtm.2024.101211_bib10","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2008-01-131417","article-title":"Intra-articular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX","volume":"112","author":"Sun","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101211_bib11","series-title":"Adeno-associated Virus as a Mammalian DNA Vector","first-page":"21","author":"Salganik","year":"2017"},{"key":"10.1016\/j.omtm.2024.101211_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.joca.2012.11.002","article-title":"Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stress","volume":"21","author":"Kyostio-Moore","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.omtm.2024.101211_bib13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.joca.2011.04.009","article-title":"Single intra-articular injection of adeno-associated virus results in stable and controllable in\u00a0vivo transgene expression in normal rat knees","volume":"19","author":"Payne","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.omtm.2024.101211_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243359","article-title":"Comparative intra-articular gene transfer of seven adeno-associated virus serotypes reveals that AAV2 mediates the most efficient transduction to mouse arthritic chondrocytes","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101211_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/hum.2006.174","article-title":"Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype","volume":"18","author":"Boissier","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib16","doi-asserted-by":"crossref","first-page":"27001","DOI":"10.1073\/pnas.1915974116","article-title":"Sources of off-target expression from recombinase-dependent AAV vectors and mitigation with cross-over insensitive ATG-out vectors","volume":"116","author":"Fischer","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101211_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2024.101211_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtm.2024.101211_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2011.00204","article-title":"Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity","volume":"2","author":"Bartel","year":"2011","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omtm.2024.101211_bib20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/pathogens11070756","article-title":"Fantastic AAV Gene Therapy Vectors and How to Find Them-Random Diversification, Rational Design and Machine Learning","volume":"11","author":"Becker","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.omtm.2024.101211_bib21","doi-asserted-by":"crossref","first-page":"11556","DOI":"10.1128\/JVI.01536-06","article-title":"Structurally Mapping the Diverse Phenotype of Adeno-Associated Virus Serotype 4","volume":"80","author":"Govindasamy","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.omtm.2020.06.003","article-title":"Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity","volume":"18","author":"Pei","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101211_bib23","doi-asserted-by":"crossref","first-page":"e00332-19","DOI":"10.1128\/JVI.00332-19","article-title":"Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses","volume":"93","author":"Albright","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib25","first-page":"505","article-title":"Hyaluronic acid synthase-2 gene transfer into the joints of Beagles by use of recombinant adeno-associated viral vectors","volume":"79","author":"Kyostio-Moore","year":"2018","journal-title":"AJVR (Am. J. Vet. Res.)"},{"key":"10.1016\/j.omtm.2024.101211_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/gen.40.09.04","article-title":"Gene Therapy: It Is Time to Talk about High-Dose AAV: The deaths of two children with X-linked myotubular myopathy in the ASPIRO trial prompts a reexamination of vector safety","volume":"40","author":"Paulk","year":"2020","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"10.1016\/j.omtm.2024.101211_bib27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV Serotypes 1\u20139 Mediated Gene Expression and Tropism in Mice After Systemic Injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib28","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22115.1","article-title":"Recent advances in the treatment of osteoarthritis","volume":"9","author":"Gr\u00e4ssel","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.omtm.2024.101211_bib29","article-title":"Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101211_bib30","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.7150\/ijms.56760","article-title":"Cellular and Tissue Selectivity of AAV Serotypes for Gene Delivery to Chondrocytes and Cartilage","volume":"18","author":"Yoon","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.omtm.2024.101211_bib31","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/JVI.78.6.3110-3122.2004","article-title":"Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors","volume":"78","author":"Thomas","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1128\/JVI.02093-13","article-title":"Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes","volume":"88","author":"Salganik","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib33","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101211_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2021.04.010","article-title":"Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids","volume":"21","author":"Cabanes-Creus","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101211_bib35","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1128\/JVI.00675-12","article-title":"Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles","volume":"86","author":"Li","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omtm.2024.101211_bib37","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1021\/acs.jpcb.7b02569","article-title":"Impact of Hydrogen Bonding in the Binding Site between Capsid Protein and MS2 Bacteriophage ssRNA","volume":"121","author":"Poudel","year":"2017","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.omtm.2024.101211_bib38","unstructured":"Warischalk, J.K. Uncovering structural components of the adeno-associated viral capsid that can be modified to improve clinical gene therapy outcomes. 142."},{"key":"10.1016\/j.omtm.2024.101211_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9_10","article-title":"Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids","volume":"1382","author":"Castle","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2024.101211_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101211_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1023\/B:JOCI.0000019781.64421.5c","article-title":"Immune Response Against Gene Therapy Vectors: Influence of Synovial Fluid on Adeno-Associated Virus Mediated Gene Transfer to Chondrocytes","volume":"24","author":"Cottard","year":"2004","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.omtm.2024.101211_bib42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2024.101211_bib44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2024.101211_bib45","doi-asserted-by":"crossref","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101211_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.857276","article-title":"Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients","volume":"13","author":"Gross","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101211_bib47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/gt.2015.21","article-title":"scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy","volume":"22","author":"Goodrich","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2024.101211_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105235","article-title":"Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome","volume":"149","author":"Matagne","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2024.101211_bib49","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1073\/pnas.0813207106","article-title":"A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in\u00a0vivo selection","volume":"106","author":"Yang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101211_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In\u00a0Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101211_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.virol.2014.02.017","article-title":"AAV8 capsid variable regions at the\u00a0two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating","volume":"454\u2013455","author":"Tenney","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2024.101211_bib52","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.1128\/JVI.00622-13","article-title":"Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common Regions","volume":"87","author":"Gurda","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib53","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1128\/JVI.00218-12","article-title":"Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8","volume":"86","author":"Gurda","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101211_bib54","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1038\/s41598-021-88614-9","article-title":"Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies","volume":"11","author":"Ito","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2024.101211_bib55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/gt.2012.46","article-title":"Distinct transduction difference between adeno-associated virus type 1 and type 6 vectors in human polarized airway epithelia","volume":"20","author":"Yan","year":"2013","journal-title":"Gene Ther."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T17:14:39Z","timestamp":1722100479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2329050124000275"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101211","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationally engineered novel AAV capsids for intra-articular gene delivery","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101211"}}